Suzhou Ribo Life Science Co., Ltd. releases latest progress in siRNA kidney-targeted delivery at American Society of Nephrology (ASN) Kidney Week -Suzhou Ribo Life Science Co., Ltd. Technology Co., Ltd.

Recently, Suzhou Ribo Life Science Co., Ltd. announced an important research result at the American Society of Nephrology Kidney Week (ASN Kidney Week) held in Texas, USA: kidney-specific targeted delivery of siRNA through independently developed RiboPepSTAR™ conjugation technology. This study further validates the technical advantages of Suzhou Ribo Life Science Co., Ltd.'s kidney targeting platform - it can achieve precise silencing of target genes in specific cell types in the kidney, opening up a new path for the treatment of chronic kidney disease (CKD). Preclinical research data shows that this delivery system achieves specific uptake into proximal renal tubule cells in cross-species models from rodents to non-human primates (NHP), with a target gene silencing efficiency of up to 80%. In addition, in rodent models of type 2 diabetes and CKD, while achieving efficient and specific silencing of relevant target genes in kidney tissue, significant improvements in corresponding drug efficacy indicators were also observed. There are still huge unmet clinical needs in chronic kidney disease, and this breakthrough technology brings new hope to the field of kidney disease treatment. By precisely targeting specific cell types in the kidney, it is expected to develop more targeted and effective siRNA innovative therapies. Suzhou Ribo Life Science Co., Ltd. will accelerate its transformation into clinical application and provide new treatment options for more than 850 million chronic kidney disease patients worldwide.